Localized grey matter atrophy in multiple sclerosis: A meta-analysis of voxel-based morphometry studies and associations with functional disability

Lansley, Joseph; Mataix‐Cols, David; Grau, Miguel Murcia; Raduà, Joaquim; Sastre‐Garriga, Jaume

doi:10.1016/j.neubiorev.2013.03.006

Cited by 105 publications

(73 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, although similarly reduced GM tissue probabilities in the thalamus were obtained for both MSF and MS0 as compared to HC (consistent with published data [11,[30][31][32][33]), we found a significant reduction in the global GM fraction for MSF. Additionally, for MSF, clearly lower FA and higher MD values in the thalamus were observed than those for MS0, indicating the important role of this region in early MS fatigue.…”

Section: Discussionsupporting

confidence: 92%

Structural correlates for fatigue in early relapsing remitting multiple sclerosis

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Structural correlates for fatigue in early relapsing remitting multiple sclerosis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It is known that GMF decreases progressively during MS course 29 and appears to be associated with accumulation of physical and cognitive disabilities 18,19 . This GMF loss occurs in varying degrees, and with a different regional distribution among disease phenotypes, but it is already detectable at the earliest disease stages 20 . A widespread pattern of GM atrophy was found in several previous VBM studies.…”

Section: Discussionmentioning

confidence: 99%

CSF β-amyloid predicts prognosis in patients with multiple sclerosis

et al. 2018

View full text Add to dashboard Cite

Background: The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognised, hence reliable biomarkers are needed.Objectives: To investigate the prognostic role of cerebrospinal fluid (CSF) Amyloid beta1-42 (A) levels by the determination of a cut-off value to classify patients in slow and fast progressors. To evaluate possible association with white (WM) and grey matter (GM) damage at early disease stages.Methods: Sixty patients were recruited and followed-up for three to five years. Patients underwent clinical assessment, CSF analysis to determine Aβ levels, and brain MRI (at baseline and after 1 year). T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads.Results: Lower CSF Aβ levels were observed in patients with a worse follow-up EDSS (r=−0.65, p<0.001).The multiple regression analysis confirmed CSF Aβ concentration as a predictor of patients' EDSS increase (r=−0.59, p<0.0001). Generating a receiver operator characteristic curve, a cut-off value of 813 pg/ml was determined as the threshold able to identify patients with worse prognosis (95%CI 0.690-0.933, p=0.0001). No differences in CSF tau and NfL levels were observed (p>0.05).Conclusions: Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.

show abstract

“…Over the past 15 years, VBM has been used successfully to investigate a wide range of neurological and psychiatric disorders including, but not limited to, Alzheimer's disease (Li et al, 2012), Parkinson's disease (Pan et al, 2013), multiple sclerosis (Lansley et al, 2013), unipolar (Lai, 2013) and bipolar (Selvaraj et al, 2012) depression, anxiety disorders (Radua et al, 2010) and psychosis (Honea et al, 2005;Bora et al, 2011Mechelli et al, 2011. In addition, VBM has been used to compare groups of healthy subjects who differ with respect to biological or environmental variables of interest such as age (Kennedy et al, 2009;Takahashi et al, 2011), gender (Takahashi et al, 2011;Sacher et al, 2013), number of spoken languages (Mechelli et al, 2004), and exposure to stressful life events (Papagni et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

False positive rates in Voxel-based Morphometry studies of the human brain: Should we be worried?

Scarpazza

Tognin

Frisciata

et al. 2015

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Voxel-based Morphometry (VBM) is a widely used automated technique for the analysis of neuroanatomical images. Despite its popularity within the neuroimaging community, there are outstanding concerns about its potential susceptibility to false positive findings. Here we review the main methodological factors that are known to influence the results of VBM studies comparing two groups of subjects. We then use two large, open-access data sets to empirically estimate false positive rates and how these depend on sample size, degree of smoothing and modulation. Our review and investigation provide three main results: (i) when groups of equal size are compared false positive rate is not higher than expected, i.e. about 5%; (ii) the sample size, degree of smoothing and modulation do not appear to influence false positive rate; (iii) when they exist, false positive findings are randomly distributed across the brain. These results provide reassurance that VBM studies comparing groups are not vulnerable to the higher than expected false positive rates that are evident in single case VBM.

show abstract

Localized grey matter atrophy in multiple sclerosis: A meta-analysis of voxel-based morphometry studies and associations with functional disability

Cited by 105 publications

References 70 publications

Structural correlates for fatigue in early relapsing remitting multiple sclerosis

Structural correlates for fatigue in early relapsing remitting multiple sclerosis

CSF β-amyloid predicts prognosis in patients with multiple sclerosis

False positive rates in Voxel-based Morphometry studies of the human brain: Should we be worried?

Contact Info

Product

Resources

About